StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
STLNStarling Oncology, Inc.
stockpulse.co.kr
Nasdaq
$6.71▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

5
  • 9.2Pre-market26.09.02 09:41filed
    8-KKey event#●●●

    Starling Oncology, Inc.

    On September 1, 2026, director Brad Hively notified the company of his decision not to stand for re-election at the 2027 annual meeting. While he will remain a director until the meeting, he has immediately resigned from his roles as Vice Chairman and as a member of all board committees.…more

    $6.71+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 8.24After-hours26.08.25 06:11
    4Ownership

    Starling Oncology, Inc.

    Brad Hively, an insider of Starling Oncology, Inc., filed a Form 4 on August 24, 2026, reporting a change in beneficial ownership of securities as of August 21, 2026. This filing serves as the official record of the insider's equity transaction.…more

    $6.71+0.00%vs prev close
    View filingShare
  • 8.21After-hours26.08.22 06:25
    8-KKey event

    Starling Oncology, Inc.

    Starling Oncology entered into a revolving credit agreement for up to $25 million with Gemino Healthcare Finance on August 20, 2026. As of August 21, 2026, $4.75 million has been drawn, with proceeds intended for working capital and general corporate purposes. The facility matures on August 20, 2029, and is secured by a first-priority interest in the company's assets.…more

    $6.71+0.00%vs prev close
    View filingShare

4 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 10.1After-hours26.10.02 05:14
    #●●●#●●●

    Starling Oncology Highlights Participation in Major Industry Conferences…more

    Starling Oncology showcased its value-based cancer care model and clinical platform insights at several recent and upcoming industry forums. As these presentations focus on thought leadership without specific financial or contractual updates, the impact remains neutral.…more

    $6.71+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 8.24Pre-market26.08.24 22:00

    ●●●●●●●● ●●●●● ●●●●●●

    Starling Oncology executives will participate in the Wells Fargo Healthcare Conference on September 8 to discuss the company's operations. As this is a standard investor relations event, it is expected to have a neutral impact on the stock price.…more

    $6.71+0.00%vs prev close
    Read sourceShareGlobeNewswire

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →